Search
forLearn
5 / 801 resultslearn Calcipotriene
learn retinoic acid
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn Piroctone Olamine
Research
5 / 628 results
research Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in the Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design
The combination of cyclosporine and PUVA might help treat severe alopecia areata.
research NON-PSORALEN TREATMENT OF VITILIGO. PART II. LESS COMMONLY USED AND EXPERIMENTAL THERAPIES
Some alternative vitiligo treatments show promise, but none are as effective as psoralens and UVA.
research Infant alopecia universalis: role of topical PUVA (psoralen ultraviolet A) radiation
Topical PUVA and tacrolimus ointment can effectively and safely treat infant alopecia universalis.
research CHARACTERIZATION OF PHOTOSENSITIZING EFFECTS BY TOPICAL DELIVERY OF ALPHA-TERTHIENYL AND UVA
Topical alpha-terthienyl with UVA may safely treat psoriasis without cancer risk.
research Phototherapy in Childhood
Phototherapy is effective and well-tolerated for treating childhood psoriasis and pityriasis lichenoides chronica.
Community Join
5 / 1000+ resultscommunity Medications that cause extra hair growth
The post discusses the side effects of various drugs causing excess hair growth, questioning why only minoxidil is used in the hair loss industry. The conversation includes users sharing their experiences and concerns about potential side effects of these drugs, with some preferring baldness over potential health risks.
community Verteporfin being used anywhere?
community Anyone used Topical Calcipotriol (cream) or VPA ( Valproic Acid)
The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
community Would Verteporfin potentially work for scarring alopecia?
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.